drugset / Trial / NCT02134808

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808

Phase 4 Completed 71 enrolled Perry Renshaw
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP) concentrations. A secondary hypothesis is that decreased depressive symptoms measured with the Children's Depression Rating Scale-Revised (CDRS-R) and Montgomery-Asberg Depression Rating Scale (MADRS) will be reciprocally correlated with increased β-NTP concentrations.

Timeline

Start
2014-11-21
Primary completion
2017-06-27
Completion
2017-06-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Creatine Other / unclassified 10 g